logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Intercept Pharmaceuticals (ICPT) Sees Pullback from Record Gains

By  +Follow January 14, 2014 12:05PM
Share:
Tickers Mentioned:

Intercept Pharmaceuticals (ICPT) continued its wild, roller-coaster ride on Tuesday, with a second-straight day of major losses. Intercept made news last week after its treatment for fatty liver disease, obeticholic acid (OCA), had a Phase II clinical trial halted early because of its efficacy. Shares spiked, then jumped again on the second day after the stock received a raft of massive upgrades from major analysts.

However, this week appears to have seen Intercept return to earth. Shares dropped nearly 20 percent on Monday, and Tuesday saw losses in excess of 30 percent, making the two-day loss nearly 45 percent of its share value. That still has Intercept sporting a five-day gain approaching 450 percent, so investors are hardly sweating recent losses, but it does have the stock returning from the rarified air it reached by the close of markets on Friday.

ICPT Sheds Value on CEO Comments

The plummet for Intercept could be attributed to comments from CEO Mark Pruzanski that his company will most likely need to partner with a larger company to bring OCA to market; a deal that would most likely eat into any potential profits.

“[Intercept’s plan] is very much to build a commercial capability,” the he said in a phone interview with Bloomberg. “But large pharmaceutical companies are very good at this kind of thing. And the overarching responsibility here is to do what we can in a responsible way to get” OCA to patients if it’s approved.

“If that can be done in a more expedited fashion with a partner, that’s something we should consider,” he continued.

However, while these comments from Monday are clearly a factor, profit-taking by traders satisfied with last week’s massive gains and anticipating a market pull-back is probably a contributing factor as well as share-volume continued at very high levels.

Concerns Over Cholesterol Levels in OCA Patients Also a Factor

The revelation that the study showed rising cholesterol levels for the patients taking OCA as compared to those on a placebo could also be weighing on Intercept’s stock. The details of the study were included in a Sunday press release from Intercept.

"OCA is an FXR agonist and we have known for a long time that it is involved in many aspects of lipid metabolism," said Pruzanski in the release. "An important part of the rationale for advancing our drug in NASH is that by activating FXR in the liver, we believe that it reduces the excess lipid load which is a causal factor in the disease. In addition, there is preclinical evidence that by activating FXR systemically, OCA is able to shunt excess lipids away from collecting in arteries and other organs which could also be beneficial. It is in any case clear that the lipid changes seen in OCA-treated patients are part of a complex set of mechanisms and we are already conducting further studies to gain a more complete understanding of the clinical implications."

The timing of the release and the major decline in shares would seem to indicate that the cholesterol concerns may also be part of the picture this week.

“[While the cholesterol] link is not new news, we believe many investors are seeing it now for the first time,” wrote Oppenheimer & Co. analyst Akiva Felt in a note to clients.

While the Phase II trial showed promising results, some still noted that OCA is still far from approval even if it appears nearly certain to reach that end point.

“What we have is a proof of concept study,” said Nezam Afdhal, head of hepatology at Beth Israel Deaconess Medical Center in Boston. “‘How that becomes a registration trial and an approvable drug is a million-dollar question.’’

ICPT Continues to Move Price for Galectin, Others

The explosion of Intercept’s stock, as well as that of other pharma companies developing similar therapies, indicates that the potential for a successful treatment for fatty liver disease, which is estimated to affect 5 percent of the population, took the markets by surprise to some degree.

And, once again, the markets appeared to treat companies with potential treatments for fatty liver disease as a monolith to some degree, with Intercept's declines appearing to trigger similar declines among its competitors in the fatty liver disease sphere.

Shares in Galectin Therapeutics (GALT) plunged over 12 percent Tuesday to make its two-day losses over 20 percent, while Conatus Pharmaceuticals (CNAT) lost almost 2.75 percent Tuesday for two-day losses just under 20 percent.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Signup for our daily newsletter and get our best articles emailed right to you!

Results for icpt
Kauri Capital
5 Sep 15 02:11:08
RT @VERBEECK_A: $GLD $GNFT $ICPT $IMC #NASH . Immuron investor presentation. Initiate Phase 2 Trial of IMM-124E http://t.co/Ywjsk9t6EB
Kauri Capital
5 Sep 15 02:11:03
RT @VERBEECK_A: RedChip #NASH Immuron compared to its peers $ICPT, $RPTP, $GNFT, $ENTA . http://t.co/5ykjKjnXsQ
Kauri Capital
5 Sep 15 02:11:01
RT @VERBEECK_A: $ICPT David Shapiro SELLS in 2015 more than 19'000 Shares of Intercept Pharmaceuticals. Analyst reco BUY :) http://t.co/5Da…
The Biotech Trader
4 Sep 15 21:00:43
Check out the free Friday Biotech Breakdown! $IBB $COMP $BIIB $GILD $ICPT http://t.co/aDtIKj90v5
Britney Salvato
4 Sep 15 16:54:06
RT @asclepiacap: RBC List of upcoming 2015 “events” in coverage and estimated impact $BIIB $XNPT $ARWR $DYAX $CELG $BMRN $ICPT $CELG http:/…
emmanuel
4 Sep 15 15:41:52
RT @okim59: Wedbush Reaffirms “Buy” Rating for Intercept Pharmaceuticals $ICPT http://t.co/U6DsZs0Grt
Nara
4 Sep 15 15:38:03
JBEM picks average 300%, latest is GNSZ w/ data in 3 days, DD here: https://t.co/gv9He7HRvh $CFRX $PTIE $ZSPH $ICPT
True about ...
4 Sep 15 13:58:44
RT @GeryDIVRY: $ICPT Wedbush analyst Liana Moussatos reiterated an Outperform rating and $493 target on Intercept Pharmaceuticals BUT ..
CTchoung
4 Sep 15 13:54:01
RT @okim59: Wedbush Reaffirms “Buy” Rating for Intercept Pharmaceuticals $ICPT http://t.co/U6DsZs0Grt
Okim59
4 Sep 15 11:11:44
Wedbush Reaffirms “Buy” Rating for Intercept Pharmaceuticals $ICPT http://t.co/U6DsZs0Grt
WKRB News
4 Sep 15 10:37:15
Wedbush Reaffirms “Buy” Rating for Intercept Pharmaceuticals $ICPT http://t.co/HQts45fbUS
Carine
4 Sep 15 10:14:35
RT @techwhitepapers: The NASH "fight" will come to a clash @ The Liver Meeting® 2015 Nov14 .. $ICPT, $GLMD, $GNFT , $GILD will present deve…
TimeForGrowth
4 Sep 15 10:14:02
$ICPT: Wall Street analysts bullish on ICPT's earnings growth: http://t.co/hfLijOn9jc http://t.co/1NinRMa5yw
Giua Clst
4 Sep 15 10:04:12
RT @techwhitepapers: The NASH "fight" will come to a clash @ The Liver Meeting® 2015 Nov14 .. $ICPT, $GLMD, $GNFT , $GILD will present deve…
Market Realist
4 Sep 15 09:06:05
IBB and XBI Underperform Benchmark Indexes for August 10-17, 2015 $IBB $XBI $MYL $ICPT http://t.co/KFQYNlE1nx
The Biotech Trader
4 Sep 15 09:00:09
Check out the free Friday Biotech Breakdown! $IBB $COMP $BIIB $GILD $ICPT http://t.co/aDtIKj90v5
Thomas F.R.
4 Sep 15 08:38:37
RT @techwhitepapers: The NASH "fight" will come to a clash @ The Liver Meeting® 2015 Nov14 .. $ICPT, $GLMD, $GNFT , $GILD will present deve…
Lucretia
4 Sep 15 08:36:15
$ICPT Wedbush Maintains Outperform on Intercept Pharmaceuticals Inc (ICPT) on Back ... http://t.co/oLkqeMxxN6
Jeffrey Blake
4 Sep 15 08:36:01
$ICPT Intercept Pharmaceuticals Receives Consensus Recommendation of "Buy" from ... http://t.co/T6qkl3hdNg
Okim59
4 Sep 15 08:35:52
RT @techwhitepapers: The NASH "fight" will come to a clash @ The Liver Meeting® 2015 Nov14 .. $ICPT, $GLMD, $GNFT , $GILD will present deve…
TooTiX
4 Sep 15 07:09:30
RT @techwhitepapers: The NASH "fight" will come to a clash @ The Liver Meeting® 2015 Nov14 .. $ICPT, $GLMD, $GNFT , $GILD will present deve…
True about ...
4 Sep 15 06:37:33
RT @techwhitepapers: The NASH "fight" will come to a clash @ The Liver Meeting® 2015 Nov14 .. $ICPT, $GLMD, $GNFT , $GILD will present deve…
Florida Biotech
4 Sep 15 06:10:56
RT @BentheFidler: East Coast #Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More http://t.co/AXJfUWTlSC $ALNY $FOLD $SAGE $ICPT $TSRO $…
Michael Torres, PhD
4 Sep 15 05:50:37
RT @BentheFidler: East Coast #Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More http://t.co/AXJfUWTlSC $ALNY $FOLD $SAGE $ICPT $TSRO $…
Ben Fidler
4 Sep 15 05:47:58
East Coast #Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More http://t.co/AXJfUWTlSC $ALNY $FOLD $SAGE $ICPT $TSRO $BMY $ARIA $TTPH
Joe Librescu
4 Sep 15 05:24:41
The NASH "fight" will come to a clash @ The Liver Meeting® 2015 Nov14 .. $ICPT, $GLMD, $GNFT , $GILD will present developments.
Rose C. Perri
4 Sep 15 04:40:13
RT @TraderBiotech: Check out the free Friday Biotech Breakdown! $IBB $COMP $BIIB $GILD $ICPT http://t.co/aDtIKj90v5
Nara
3 Sep 15 21:08:46
$CFRX $PTIE $ZSPH $ICPT $SSRG $MACK $BSPM $NHC 'JBEM' picks. Free membership. No P
The Biotech Trader
3 Sep 15 21:00:31
Check out the free Friday Biotech Breakdown! $IBB $COMP $BIIB $GILD $ICPT http://t.co/aDtIKj90v5
PennyStock Zone
3 Sep 15 16:57:24
http://t.co/T1OENoRe1I <- Fous4x2 review invest in your #trading education! $ABEV $ICPT $AA $AMBA #stocks $FB $TWTR
Nara
3 Sep 15 16:01:20
$ICPT $ONCY $PODD $STAA Nice close today for GNSZ. Next week conf.Find details here: https://t.co/gv9He7HRvh
GROSSE14
3 Sep 15 15:00:38
RT @R4inb0w_: Read A Study of NASH Competitors : "Why I remain a shareholder of GENFIT" by @GeryDIVRY $GNFT $ICPT $GILD #FattyLiver http://…
Clément d'Espagnac
3 Sep 15 13:45:16
RT @adamfeuerstein: $NK had worst August for biotech stocks which matter -41% $CLDX -35% $ZIOP -30% $OPK -30% $OVAS -29% $ICPT -28% $ONCE…
True about ...
3 Sep 15 13:43:01
RT @InsiderWire: $ICPT | Intercept Pharmaceuticals, Inc. is down 27% since we reported $3,016,666 of insider selling on ... - http://t.co/G…
InsiderTradingWire
3 Sep 15 13:00:35
$ICPT | Intercept Pharmaceuticals, Inc. is down 27% since we reported $3,016,666 of insider selling on ... - http://t.co/GQ9ZcI8E4x
Rose C. Perri
3 Sep 15 12:42:13
RT @TraderBiotech: Check out the free Friday Biotech Breakdown! $IBB $COMP $BIIB $GILD $ICPT http://t.co/aDtIKj90v5
PennyStock Zone
3 Sep 15 10:22:40
***REVIEW***: Super Alerts on http://t.co/1EZI2QRyUa stock picking service: http://t.co/wQ3KRVzufM $CBI $MA $V $ICPT $DECK $GOOG $EGO
Nara
3 Sep 15 09:09:42
$CFRX $PTIE $ZSPH $ICPT $SSRG $MACK $BSPM $NHC 'JBEM' picks. Free membership. No Pump Dump. Extensive DD https://t.co/wZhLK4QXda
Egor Romanyuk
3 Sep 15 09:04:14
Sold $ICPT 200 calls for +$7000 and covered $ICPT 175 put for +$800.
The Biotech Trader
3 Sep 15 09:00:06
Check out the free Friday Biotech Breakdown! $IBB $COMP $BIIB $GILD $ICPT http://t.co/aDtIKj90v5
Egor Romanyuk
3 Sep 15 08:59:39
"@barna $ICPT let's do another day like this tomorrow. 194 please :)" How's that for a guess. On the DOT
US Banking News
3 Sep 15 08:36:18
Intercept Pharmaceuticals Receives Consensus Recommendation of “Buy” from Brokerages $ICPT http://t.co/BJ3B5Dr1ZG
Ticker Report
3 Sep 15 08:25:31
Intercept Pharmaceuticals Receives Consensus Recommendation of “Buy” from Brokerages $ICPT http://t.co/ZwRE0YpGcb
Dakota Financial
3 Sep 15 08:24:57
Intercept Pharmaceuticals Receives Consensus Recommendation of “Buy” from Brokerages $ICPT http://t.co/qO8WaAWM4c
Consumer News
3 Sep 15 08:22:55
Intercept Pharmaceuticals Receives Consensus Recommendation of “Buy” from Brokerages $ICPT http://t.co/5Co4YgF0IS #acn
ProTradersNews
3 Sep 15 08:16:02
$ICPT: Intercept Pharmaceuticals Receives Consensus Recommendation …: http://t.co/upPZem8nEx
Nara
3 Sep 15 07:55:40
$ZIOP $LPCN $SCAI $ICPT $CAH $INSM JBEM's new pick is GNSZ.Upcoming catalyst.Details here: https://t.co/gv9He7HRvh
maryalice roudabush
3 Sep 15 07:54:10
RT @asclepiacap: RBC List of upcoming 2015 “events” in coverage and estimated impact $BIIB $XNPT $ARWR $DYAX $CELG $BMRN $ICPT $CELG http:/…
Nicolas Jlt
3 Sep 15 02:41:15
RT @R4inb0w_: Read A Study of NASH Competitors : "Why I remain a shareholder of GENFIT" by @GeryDIVRY $GNFT $ICPT $GILD #FattyLiver http://…
Gery DIVRY
3 Sep 15 02:39:00
RT @R4inb0w_: Read A Study of NASH Competitors : "Why I remain a shareholder of GENFIT" by @GeryDIVRY $GNFT $ICPT $GILD #FattyLiver http://…
				
				
By  +Follow January 14, 2014 12:05PM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

Welcome to Equities.com's Small-Cap Throwdown


These Analysts Called Apple's (AAPL) Collapse, Here's What They're Saying Now

7 Dow Stocks Worth Owning and a Lot that Aren't

Sprint Turnaround Has Begun


Saving the

Small-Cap Market

 

Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN